#research #structuralbiology #antifungalresearch

Structural characterization and inhibition of carbonic anhydrase from Candida parapsilosis
(Dostál et al., Vrábel, Heidingsfeld, Pichová) – Journal of Structural Biology: X: doi.org/10.1016/j.yj...

@iocbprague.bsky.social @czechacademy.bsky.social

Breakthrough Invasive Mould Infections Under Posaconazole Prophylaxis in Patients With Haematologic Malignancies: A Case–Control Study Background Posaconazole (POS) prophylaxis is recommended for the prevention of invasive mould infections among patients with haematologic cancer and prolonged neutropenia or following allogeneic hae...

🚨 New study alert!
Breakthrough invasive mould infections can still occur under posaconazole prophylaxis in patients with haematologic malignancies—linked to high mortality despite adequate drug levels. Read the full case–control study 👉 doi.org/10.1111/myc....

#Haematology #AntifungalResearch

💡 New in NARMME: TRL1 enzyme from Candida glabrata changes shape to control RNA repair, vital for fungal survival. Its absence in humans makes it a promising antifungal drug target.

📖 Read more: doi.org/10.1093/narm...

#TRL1 #RNARepair #AntifungalResearch #DrugDiscovery #NARMME #OpenAccess

Antifungal Properties of Polycephalomyces nipponicus (Ascomycetes) against Candida albicans: Potential for Novel Therapeutic Development

dl.begellhouse.com/journals/708...

#AntifungalResearch #DrugDiscovery #CandidaAlbicans

Humanized Candida and NanoBiT Assays Expedite Discovery of Bdf1 Bromodomain Inhibitors With Antifungal Potential The fungal BET protein Bdf1 is a potential antifungal target in pathogenic Candida species requiring the inhibition of both its bromodomains. Humanized Candida strains and NanoBiT complementation ass...

🚀 Excited to share our latest research on antifungal drug discovery! 🍄💊
We use humanized Candida models and NanoBiT assays to identify selective inhibitors of the Bdf1 bromodomain, a promising antifungal target.
doi.org/10.1002/advs...
#AntifungalResearch #DrugDiscovery

A 🧵 1/6 👇

🚀 Just published, our review of direct antifungal drug delivery approaches for invasive fungal infections.

Evidence is still limited, but trials are underway. Extra options, fewer side effects, better patient outcomes 🚀

#AntifungalResearch #HealthcareInnovation

pubmed.ncbi.nlm.nih.gov/39317940/